Iron chelation therapy in aceruloplasminaemia: Study of a patient with a novel missense mutation

52Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

We describe a novel missense mutation of ceruloplasmin in a patient with aceruloplasminaemia causing the replacement of a neutral amino acid (phenylalanine) with a polar one (serine) at position 198, probably leading to abnormal folding and secretion of the protein. The patient showed mild microcytic anaemia, mild hepatic iron overload, and marked brain iron overload. Six months of therapy with deferiprone was ineffective in removing iron from the tissues. Deferoxomine was more efficient in removing excess iron from the liver but aggravated the disease related anaemia. After more than one year of chelation treatment, the brain magnetic resonance imaging signal did not change. Overall, these findings indicate that treatment of iron overload in aceruloplasminaemia is a difficult challenge and that new iron chelators, more efficient in crossing the blood-brain barrier, are needed.

Cite

CITATION STYLE

APA

Mariani, R., Arosio, C., Pelucchi, S., Grisoli, M., Piga, A., Trombini, P., & Piperno, A. (2004). Iron chelation therapy in aceruloplasminaemia: Study of a patient with a novel missense mutation. Gut, 53(5), 756–758. https://doi.org/10.1136/gut.2003.030429

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free